Sylvie Deuffic-Burban
机构: Chercheur, Inserm
每年引用次数
引用次数
引用: 4,457
H-指数: 34
I10-指数 : 64
出版物: 152
Modeling of the natural history of HCV infection predicts a dramatic increase in the HCC mortality burden
A. J. Valleron , S. Deuffic , T. Poynard , L. Buffat
Hepatology 26(4 Part 2 499
1997
Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe
S. Deuffic , T. Poynard , A. -J. Valleron
Journal of Viral Hepatitis 6 ( 5) 411 -413
90
1999
Predicted Effects of Treatment for HCV Infection Vary Among European Countries
Sylvie Deuffic–Burban , Pierre Deltenre , Maria Buti , Tommaso Stroffolini
Gastroenterology 143 ( 4) 974 -985
154
2012
1362 THE AVAILABILITY OF DIRECT ACTING ANTIVIRALS (DAA) IN 2012: A FRENCH MODEL-BASED ANALYSIS OF THE INCREASED NUMBER OF PATIENTS TREATED FOR CHRONIC HCV INFECTION
S. Deufflc-Burban , P. Mathurin , S. Pol , C. Larsen
Journal of Hepatology 54
1
2011
Severe Liver Disease Related to Chronic Hepatitis C Virus Infection in Treatment-Naive Patients: Epidemiological Characteristics and Associated Factors at First Expert Centre Visit, France, 2000 to 2007 and 2010 to 2014
Alice Sanna , Yann Le Strat , Françoise Roudot-Thoraval , Sylvie Deuffic Burban
Eurosurveillance 22 ( 30) 30582
5
2017
Routine HIV screening in France: an estimation of clinical impact and cost-effectiveness.
A. D. Paltiel , C. E. Sloan , F. Lert , D. Costagliola
Bulletin Épidémiologique Hebdomadaire 455 -460
2010
Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France
S. Dharancy , A. Hollebecque , V. Canva , S. Deuffic-Burban
Research Papers in Economics
73
2008
Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness
L. Bocket , P. Choisy , S. Deuffic-Burban , F. Ajana
Antiviral Therapy 10 ( 2) 247 -254
91
2005
Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States.
S. Deuffic-Burban , T. Poynard , M. S. Sulkowski , J. B. Wong
Journal of Viral Hepatitis 14 ( 2) 107 -115
140
2007
Risk Factors for Hepatitis C Virus Transmission to Health Care Workers after Occupational Exposure: A European Case-Control Study
Y. Yazdanpanah , G. De Carli , B. Migueres , F. Lot
Clinical Infectious Diseases 41 ( 10) 1423 -1430
157
2005
L-01 Polymorphismes de la protéase du VIH-1 : impact sur l’efficacité d’un premier traitement antirétroviral comportant le lopinavir
K. Champenois , S. Deuffic-Burban , L. Cotte , P. André
Medecine Et Maladies Infectieuses 38
2008
Blood-borne viruses in health care workers: prevention and management
Sylvie Deuffic-Burban , Elisabeth Delarocque-Astagneau , Dominique Abiteboul , E Bouvet
Journal of Clinical Virology 52 ( 1) 4 -10
74
2011
Expected increase in prevalence of HCV-related cirrhosis and its complications in the United States: No effect of current antiviral treatment coverage?
S. Deuffic-Burban
Gastroenterologie Clinique Et Biologique 34 ( 11) 577 -579
4
2010
49 LIFETIME COSTS ATTRIBUTABLE TO CHRONIC HEPATITIS C FROM THE FRENCH HEALTHCARE PERSPECTIVE (ANRS N°12188)
M. Schwarzinger , S. Deuffic-Burban , V. Mallet , S. Pol
Journal of Hepatology 58 S21 -S22
13
2013
O89 Impact Of New Daa-Containing Regimens On Hcv Transmission Among Injecting Drug Users (Idus): A Model-Based Analysis (Anrs 12376)
A. Cousien , V.C. Tran , M. Jauffret-Roustide , S. Deuffic-Burban
Journal of Hepatology 60 ( 1) 36 -37
3
2014
661 ULTRASONOGRAPHIC (US) SCREENING OF HEPATOCELLULAR CARCINOMA (HCC) IN COMPENSATED CIRRHOSIS DUE TO HEPATITIS C VIRUS (HCV) IMPROVES SURVIVAL: A MODELING APPROACH
A. Mourad , S. Deuffic-Burban , T. Renault-Vantroys , N. Ganne-Carrié
Journal of Hepatology 58 S269
2013
809 IMMEDIATE OR DELAYED TREATMENT INITIATION WITH “PREVIR” CONTAINING REGIMENS IN HCV-INFECTED NAIVE GENOTYPE 1 (G1) PATIENTS WITHOUT SEVERE FIBROSIS? A COST-EFFECTIVENESS ANALYSIS (ANRS N°12188)
S. Deuffic-Burban , M. Schwarzinger , V. Mallet , S. Pol
Journal of Hepatology 58 S331
2
2013
O.037 Prediction of HCV-related morbidity and mortality burden in France using the back-calculation method
S. Deuffic-Burban , J.B. Wong , A.-J. Valleron , T. Poynard
Journal of Clinical Virology 36
2006
Coût-efficacité et VHC : mise au point
S. Deuffic-Burban , S. Cossais , Y. Yazdanpanah
Journal des Anti-Infectieux 16 ( 2) 50 -63
2014
P0745 : EQ-5D utility index in French patients with chronic hepatits C (CHC) infection: severe comorbidities and perceived progression of CHC infection matter more than actual liver disease stage
M. Schwarzinger , S. Cossais , S. Deuffic-Burban , S. Pol
Journal of Hepatology 62
4
2015